Clinical Trial
NAD+ supplement shows early promise for long COVID fatigue and brain fog
Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo
A randomized controlled trial at Massachusetts General Hospital tested high-dose nicotinamide riboside, a vitamin B3 derivative, to boost NAD+ levels in people with long COVID. Although between-group differences were limited, participants who took the supplement for at least 10 weeks reported improvements in fatigue, sleep, mood, and some executive function measures compared with their own baseline, suggesting potential benefits for some individuals despite mixed overall results.
Scientists at the University of Southern California are starting a phase 2b clinical trial to test a microscopic stem cell implant aimed at restoring vision in patients with advanced dry age-related macular degeneration. The hair-thin patch seeks to replace damaged retinal cells, building on earlier research that showed safety and vision gains in some participants. Researchers hope it could offer a way to reverse vision loss where current treatments fall short.
Ti AI ṣe iroyin
The Comandante Faustino Pérez Provincial Clinical Surgical Hospital has started a clinical trial using the Cuban drug Jusvinza to treat residual polyarthritis in chikungunya survivors. The study assesses the medication's ability to reduce ongoing pain and joint inflammation. It involves 120 patients and aims to provide an affordable treatment option.